🇺🇸 FDA
Patent

US 9566294

Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

granted A61KA61K2039/505A61K31/713

Quick answer

US patent 9566294 (Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis) held by Northwest Biotherapeutics, Inc. expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Northwest Biotherapeutics, Inc.
Grant date
Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K2039/505, A61K31/713, A61K38/00, A61K45/06